Abstract | INTRODUCTION: AREAS COVERED: This review examines the in vitro and in vivo pharmacology of lonafarnib and the available clinical data for lonafarnib monotherapy and combination therapy in the treatment of solid and hematological malignancies as well as progeria, using studies identified from the PubMed database supplemented by computerized search of relevant abstracts from major cancer and hematology conferences. EXPERT OPINION:
|
Authors | Nan Soon Wong, Michael A Morse |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 21
Issue 7
Pg. 1043-55
(Jul 2012)
ISSN: 1744-7658 [Electronic] England |
PMID | 22620979
(Publication Type: Journal Article, Review)
|
Chemical References |
- Enzyme Inhibitors
- Piperidines
- Pyridines
- Farnesyltranstransferase
- lonafarnib
|
Topics |
- Apoptosis
(drug effects)
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Clinical Trials as Topic
- Enzyme Inhibitors
(administration & dosage, pharmacokinetics, pharmacology, therapeutic use)
- Farnesyltranstransferase
(antagonists & inhibitors)
- Humans
- Neoplasms
(drug therapy, enzymology, pathology)
- Piperidines
(administration & dosage, pharmacokinetics, pharmacology, therapeutic use)
- Progeria
(drug therapy, enzymology, pathology)
- Protein Prenylation
- Pyridines
(administration & dosage, pharmacokinetics, pharmacology, therapeutic use)
- Treatment Outcome
- Xenograft Model Antitumor Assays
|